| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Molecular Pharmacology,*Albert Einstein College of Medicine, Bronx; the Division of Hormone-Dependent Tumor Biology,The Albert Einstein Cancer Center, Bronx; the Divisions of Cardiology and Infectious Disease,Department of Medicine, Albert Einstein College of Medicine and The Montefiore Medical Center, Bronx; the Department of Pathology,Albert Einstein College of Medicine, Bronx; and the Department of Physiology and Biophysics,¶Albert Einstein College of Medicine, Bronx, New York
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
Caveolin-1 and -3 form 
350-kd homo-oligomers made up of 14–16 caveolin monomers. These homo-oligomers serve as the basic structural units that drive the formation of caveolae membranes. In contrast, Cav-2 either homodimerizes or forms high molecular mass hetero-oligomers with Cav-1.5-7
Cav-1 and Cav-3 are both independently necessary and sufficient to drive caveolae formation in heterologous expression systems, while Cav-2 requires the presence of Cav-1 for proper membrane targeting and stabilization. In the absence of Cav-1, Cav-2 localizes to the Golgi complex where it is degraded by the proteasome.8,9
Initially considered to be mere conduits for endocytosis, caveolae are now recognized to have pleiotropic effects on numerous cellular events. Caveolin family members have been proposed to participate in vesicular trafficking, 10 lipid metabolism, 11,12 and various signal transduction processes. The "caveolae signaling hypothesis" states that caveolae serve as an integrated platform to concentrate and modulate the activity of specific lipid-modified signaling molecules, including Src family tyrosine kinases, H-Ras, eNOS, and heterotrimeric G proteins.13-16 With the centralized role that caveolins assume in multiple cellular processes, it is not surprising that mutations within the CAV1 and CAV3 loci have been identified in human breast cancers17 and muscular dystrophy (limb girdle muscular dystrophy, type 1C; LGMD-1C), 18 respectively.
Gene deletion studies have confirmed and challenged our views of these crowded little caves. Targeted gene disruption of the Cav-1 locus in mice leads to a loss of caveolae in caveolin-1-expressing tissues, but a retention of caveolae in striated muscle tissues. The major tissue-specific defects include abnormalities in pulmonary structure and function, as characterized by hypercellularity, thickened alveolar septa, and exercise intolerance; decreased vascular tone, as assessed by aortic ring studies and determined to be secondary to eNOS activation; resistance to diet-induced obesity and fibrosis of fat pads with increasing age; and defects in caveolar endocytosis and marked hyperproliferation in mouse embryonic fibroblasts.9,19,20
Interestingly, Cav-3 null mice show a loss of caveolae specifically within muscle tissues. Myopathic changes ranging from mild to moderate were noted in skeletal muscle and characterized by variability in muscle fiber size and the presence of necrotic fibers. Although no changes were noted in the expression levels of the members of the dystrophin-glycoprotein (DG) complex, the DG complex was no longer properly targeted to cholesterol-rich lipid rafts/caveolae. In addition, the T-tubule system appeared immature and was longitudinally oriented; diffuse mislocalization of T-tubule marker proteins was also noted.21,22
Although much insight into caveolar function has been gained from the individual Cav-1 and Cav-3 knockouts, several questions remain unanswered. For example, (i) Does the persistence of tissue-specific caveolae in the single knock-outs (Cav-1 and Cav-3 null mice) allow for a functional compensation in certain tissues (ie, the heart, where 40% of the cells are non-muscle and therefore normally express Cav-1)?23
and (ii) What are the developmental and physiological consequences of a caveolae-deficient animal? These remaining questions prompted us to generate a mouse model that lacks caveolae in both muscle and non-muscle cells; this was achieved by interbreeding Cav-1 null and Cav-3 null mice, to yield Cav-1/Cav-3 double-knockout (Cav-1/3 dKO) mice.
Surprisingly, we show here that Cav-1/3 dKO mice are viable and fertile. Loss of Cav-1 and Cav-3 protein expression was verified by Western blot analysis and the pleiotropic ablation of caveolae formation was demonstrated by transmission electron microscopy. Routine histopathological examination revealed that Cav-1/3 dKO mice exhibited lung, fat, and skeletal muscle defects of comparable severity to their single-knockout counterparts. However, Cav-1/3 dKO mice displayed grossly enlarged hearts, ie, cardiomegaly, greatly exceeding those of Cav-1 KO, Cav-3 KO, and wild-type mice. Gated MRI analysis of the Cav-1/3 dKO hearts revealed a significant increase of 40% in left ventricular wall thickness. Further functional analysis using transthoracic echocardiography demonstrated an 35% increase in left ventricular wall thickness, with left ventricular dilation. Moreover, systolic function, as determined by left ventricular fractional shortening, was significantly compromised in Cav-1/3 dKO mice. Histopathological examination of sections of cardiac tissue from Cav-1/3 dKO mice demonstrated cardiac myocyte hypertrophy, generalized myocyte disorganization and myocytolysis, accompanied by chronic inflammation and fibrosis. Finally, Northern blot analysis indicated that an embryonic marker, atrial natriuretic factor (ANF), was up-regulated in ventricular samples prepared from Cav-1/3 dKO mice. The cardiac defects observed in Cav-1/3 dKO mice emphasize the importance of both caveolin isoforms for normal cardiac structure and function. Future studies will be needed to define the diastolic and systolic phenotype and address the development of contractile failure in Cav-1/3 dKO mice, such as monitoring the generation of calcium sparks24
and their exercise responses.24
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Caveolin-1, -2, and -3 mouse mAbs (used for immunoblotting;3,25,26 ) were the generous gift of Dr. Roberto Campos-Gonzalez, BD-Transduction Laboratories, Inc. The ANF cDNA was the generous gift of Dr. Jil Tardiff, Albert Einstein College of Medicine. A variety of other reagents were of the highest purity grade and were obtained from the usual commercial sources.
Animal Studies
All animals were housed and maintained in a barrier facility at the Institute for Animal Studies, Albert Einstein College of Medicine. Cav-1(-/-)/Cav-3 (-/-)-deficient mice were generated by interbreeding Cav-1 (-/-)9 and Cav-3 (-/-) mice,21 that were in a C57Bl/6 background.
Immunoblot Analysis
Mice of various genotypes were sacrificed and fat, lung, heart, muscle, and aortic tissue samples were harvested. Approximately 100 mg of a given tissue sample was then homogenized in lysis buffer (10 mmol/L Tris, pH 7.5, 50 mmol/L NaCl, 1% Triton X-100, 60 mmol/L octyl glucoside), containing protease inhibitors (Boehringer Mannheim). Tissue lysates were then centrifuged at 12,000 x g for 10 minutes to remove insoluble debris. Protein concentrations were analyzed using the BCA reagent (Pierce) and the volume required for 10 µg of protein was determined. Samples were then separated by SDS-PAGE (12.5% acrylamide) and transferred to nitrocellulose. The nitrocellulose membranes were stained with Ponceau S (to visualize protein bands), followed by immunoblot analysis. All subsequent wash buffers contained 10 mmol/L Tris pH 8.0, 150 mmol/L NaCl, 0.05% Tween-20, which was supplemented with 1% bovine serum albumin (BSA) and 2% nonfat dry milk (Carnation) for the blocking solution and 1% BSA for the antibody diluent. Primary antibodies were used at a 1: 500 dilution. Horseradish peroxidase-conjugated secondary antibodies (1:5000 dilution, Pierce) were used to visualize bound primary antibodies with the Supersignal chemiluminescence substrate (Pierce).
Transmission Electron Microscopy
Fat, lung, heart, skeletal muscle, and aortic tissue samples were fixed with 2.5% glutaraldehyde in 0.1 mol/L cacodylate buffer, postfixed with OsO4, and stained with uranyl acetate and lead citrate. Microtome sections were examined under a JEOL 1200 EX transmission electron microscope and photographed at a magnification of x16,000.9 Caveolae were identified by their characteristic flask shape, size (50–100 nm), and location at or near the plasma membrane.27,28
Preparation of Heart Paraffin Sections
Mice were sacrificed and their hearts were removed and placed in buffered formalin (10%). The tissue was fixed for 24 hours, washed in PBS for 20 minutes, dehydrated through a graded series of ethanol washes, treated with xylene for 40 minutes, and then embedded in paraffin for 1 hour at 55°C. Paraffin-embedded 5-µm-thick sections were then prepared using a Microm (Baxter Scientific) microtome and placed on superfrost plus slides (Fisher). Slides were then stained with hematoxylin and eosin (H & E), according to standard laboratory protocols. Areas of the myocardium (left ventricle and intraventricular septum) were selected for imaging. Samples were examined in a blinded fashion by one of us (S.M.F.).
Northern Blot Analysis
Mice were sacrificed and the ventricular tissue was carefully separated from atrial tissue by dissection. Total RNA was extracted from 100 mg of left ventricular tissue from each sample using Trizol reagent protocol (Gibco). Twenty micrograms of total RNA for each sample was separated using a 1.2% agarose gel under RNase-free conditions and transferred to nitrocellulose. The filters were hybridized using the ExpressHyb solution (Clontech). The blots were probed with the radiolabeled ANF cDNA.
Non-Invasive Cardiac Imaging
Gated Cardiac Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) experiments were performed using a GE Omega 9.4T vertical bore magnetic resonance system equipped with a microimaging accessory and custom-built coils designed specifically for mice. Just before each image acquisition, the heart rate was determined from the ECG, and the spectrometer gating delay was set to acquire data in diastole and systole. Multislice spin-echo imaging with an echo time of 18 ms and a repetition time of approx. 100 to 200 ms was performed. A 35-mm field of view (with a 256 x 256 pixel image matrix) was used. Short and long axis images of the heart were acquired and MRI data were processed off-line with MATLAB-based custom-designed software.
Transthoracic Echocardiography
Transthoracic echocardiography was performed on 2- and 4-month-old mice, as we described previously.29 Echocardiography was performed with mice in supine position on a heating pad set at 38°C. Light anesthesia was achieved using isoflurane inhalation.29 Continuous, standard electrocardiograms were taken from electrodes placed on the extremities. Echocardiographic images were obtained using an annular array, broadband, 10/5 MHz transducer attached to an HDI 5000 CV ultrasound system (Advanced Technology Laboratories, Bothel, WA). A small gel standoff was placed between the probe and chest. Two-dimensional and M-mode images of the heart were obtained from the basal short axis view of the heart and stored on 3/4-inch SVHS video tapes for off-line measurements using the Nova-Microsonic (Kodak) Imagevue DCR workstation (Indianapolis, IN). All measurements were made in three to six consecutive cardiac cycles and the averaged values were used for analysis. Left ventricular end-diastolic and end-systolic diameters, as well as diastolic ventricular septal and posterior wall thickness were measured from M-mode tracings. Diastolic measurements were performed at the point of greatest cavity dimension, and systolic measurements were made at the point of minimal cavity dimension, using the leading edge method of the American Society of Echocardiography.30 Additionally, the following parameters were calculated using the above-mentioned measurements: left ventricular diastolic wall thickness as the average of ventricular septal and left ventricular posterior wall thickness; left ventricular percent fractional shortening as {100 x [(end-diastolic diameter minus end-systolic diameter)/end-diastolic diameter]}; and relative wall thickness as (2 x left ventricular diastolic wall thickness)/end-diastolic diameter. Also, see this more recent review on the echocardiographic examination of the mouse.31
Note that differences between the "absolute" wall thicknesses measured using MRI and echocardiography are commonly observed and are likely due to technical factors, such as differences in the time of gating; echocardiography may underestimate these values, while MRI may overestimate these values. Most importantly, however, the relative changes measured in left ventricular wall thickness using MRI and echocardiography are in agreement, ie, an increase of 34–41% for Cav-1/3 dKO mice (see below).
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
We have previously shown the Cav-1 null mice lack caveolae in non-muscle cells (fibroblasts, adipocytes, endothelial cells), but continue to form caveolae in skeletal muscle fibers9,20 (and data not shown). Conversely, Cav-3 null mice fail to form caveolae in skeletal muscle, but show abundant caveolae in non-muscle cells, such as endothelia.21 These findings are consistent with the relatively ubiquitous expression of caveolin-1 in non-muscle cell types and the restricted tissue-specific expression of caveolin-3 in muscle cells. Thus, whole-body ablation of caveolae would require a complete loss of both caveolin-1 and caveolin-3 protein expression.
Here, we generated caveolin-1/caveolin-3 double-knockout mice by interbreeding Cav-1-null and Cav-3-null mice. Surprisingly, Cav-1/3 dKO mice are viable and fertile and exhibit no obvious external gross defects. As predicted based on their genotype, we show that Cav-1/3 dKO mice fail to express both the caveolin-1 and caveolin-3 protein products (Figure 1)
. Note that in wild-type mice, fat and lung tissues abundantly co-express the Cav-1 and Cav-2 proteins, while the Cav-3 protein is highly expressed in striated muscle tissues (cardiac and skeletal); finally, all three caveolin family members are co-expressed in smooth muscle cells (such as in the aorta).2,3,32
Western blot analysis using caveolin isoform-specific mAb probes clearly demonstrates a complete loss of Cav-1 and Cav-3 protein expression in all of the Cav-1/3 dKO tissues examined (Figure 1
, upper and lower panels). As Cav-2 requires Cav-1 for stabilization, oligomerization, and plasma membrane localization, Cav-2 protein expression is also dramatically down-regulated (by 95%) in Cav-1/3 dKO mice (Figure 1
, middle panel), as we previously reported for Cav-1 null mice.8,9
Therefore, the Cav-1/3 dKO mice are deficient in the expression of all three caveolin gene products (Cav-1, -2, and -3).
|
. In striking contrast, Cav-1/3 dKO mice show a distinct lack of morphologically identifiable caveolae in both muscle and non-muscle cells (Figures 2 and 3)
. Thus, Cav-1/3 dKO mice are the first truly caveolae-deficient mouse model. As such, whole-body ablation of caveolae formation does not affect viability in mice. In Figure 3
, electron micrographs of cardiac myocytes and adjacent endothelia from Cav-1 null mice (upper right panel) and Cav-3 null mice (lower left panel) are also shown for comparison.
|
|
Cav-1/3 dKO Mice Exhibit Dramatic Cardiac Hypertrophy as Assessed by Gated Cardiac MRI and Gross Morphology
The heart consists of 60% cardiac myocytes (that express Cav-3), while the remaining 40% is made up of non-muscle cells, ie, cardiac fibroblasts, vascular endothelial cells, and endocardium (that express Cav-1). As such, we chose to focus on the heart in Cav-1/3 dKO mice, as almost half of the cells in the heart express caveolin-1, while the other half express caveolin-3. Thus, it might be expected that Cav-1/3 dKO mice would show an additive cardiac phenotype, as compared with Cav-1 and Cav-3 single-knockout mice.
The hearts of Cav-1/3 dKO mice were first assessed non-invasively using gated MRI. Non-invasive imaging techniques allow for accurate measurement of left ventricular wall thickness and chamber diameter in an intact functional heart. This is accomplished by timing image acquisition after ventricular contraction, as determined from the electrocardiogram.
At 2 months of age, Cav-1/3 dKO mice show a significant increase in left ventricular wall thickness that exceeds wild-type mice by 41% (Table 1)
; a noticeable increase was also observed in right ventricular wall thickness (data not shown). Figure 4
shows a representative short axis (transverse) image of the hearts of Cav-1/3 dKO and wild-type mice taken at the mid-level. Note the marked increase in left ventricular wall thickness. Importantly, Cav-1 null mice and Cav-3 null mice only showed minor changes in left ventricular wall thickness (Table 1)
, suggesting that the dual ablation of both Cav-1 and Cav-3 leads to a synergistic effect. Thus, we concentrated our efforts on the characterization of the cardiac phenotype of Cav-1/3 dKO mice.
|
|
.
|
Several parameters of cardiac function were next assessed using transthoracic echocardiography. Importantly, there was no significant difference in heart rate (beats per minute) between wild-type and Cav-1/3 dKO mice, at either 2 months or 4 months of age (Table 3)
. Continuous electrocardiographic monitoring revealed no obvious conduction defects or cardiac arrhythmias in Cav-1/3 dKO mice. However, Cav-1/3 dKO hearts exhibited left ventricular hypertrophy and dilation, and showed decreased systolic function, as detailed below (Table 3)
.
|
At 2 months of age, Cav-1/3 dKO hearts exhibited significant left ventricular dilation as compared with wild-type mice, as evidenced by increases in end-diastolic diameter (Cav-1/3 dKO, 3.27 ± 0.16 vs. WT, 2.71 ± 0.13 mm, P < 0.05) and end-systolic diameter (Cav-1/3 dKO, 2.02 ± 0.07 vs. WT, 1.12 ± 0.13 mm, P < 0.05).
Hypertrophy
At 2 months of age, Cav-1/3 dKO hearts showed clear hypertrophy, with increases of 34% in interventricular septal thickness, posterior wall thickness, and left ventricular wall thickness, consistent with concentric hypertrophy.
Decreased Systolic Function
A marked reduction in left ventricular systolic function was observed in Cav-1/3 dKO hearts, as evidenced by changes in left ventricular fractional shortening (Cav-1/3 dKO, 38.33 ± 2.57 vs. WT, 58.65 ± 5.48 mm, P < 0.05). Interestingly, no further deterioration of the above cardiac parameters was noted in 4-month-old Cav-1/3 dKO mice (Table 3)
.
Histological Analysis of Cav-1/3 dKO Hearts Reveals Cardiac Myocyte Hypertrophy and Disorganization, with Inflammation and Interstitial Fibrosis
As Cav-1/3 dKO hearts show significant structural and functional changes as assessed by gated cardiac MRI and transthoracic echocardiography, Cav-1/3 dKO hearts were examined by routine histological analysis. Representative hematoxylin and eosin-stained sections of the myocardium from wild-type and Cav-1/3 dKO mice (at 2 months old) are shown in Figure 5
at various magnifications. Note that there is marked cardiac myocyte hypertrophy and disorganization, with significant chronic inflammation and interstitial fibrosis. Areas of cardiac myocyte "drop-out," eg, myocytolysis, were also observed.
|
Many forms of cardiac hypertrophy are accompanied by an increase in the expression of embryonic genes that are normally only expressed during fetal development. As such, cardiac hypertrophy leads to an activation of this fetal programming and the expression of natriuretic peptides and contractile proteins normally not expressed in adult ventricles.34 Therefore, we examined the expression of ANF, a well-established biochemical marker of ventricular hypertrophy, in ventricular tissue derived from Cav-1/3 dKO mice.
As demonstrated in Figure 6
, the ANF transcript is highly up-regulated in the Cav-1/3 dKO ventricles, but absent in wild-type control ventricular tissue. Thus, these data provide further molecular evidence that Cav-1/3 dKO mice exhibit a cardiomyopathic phenotype with significant hypertrophy.
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
95%), Cav-1/3 dKO mice are deficient in all three caveolin gene family members, ie, the first "caveolin-less" mouse. As mentioned previously, nearly 40% of the heart consists of cells expressing high levels of Cav-1 (vascular endothelium, endocardium, cardiac fibroblasts), while cardiac myocytes have abundant Cav-3 expression.3 Thus, the heart is an ideal organ to study the function of both Cav-1- and Cav-3-generated caveolae within a single tissue. A joint role for Cav-1 and Cav-3 in the development of cardiac hypertrophy is suggested by the work of multiple groups. Chronic ß-adrenergic infusion into mice induces cardiac hypertrophy with a concomitant decrease in both Cav-1 and Cav-3 expression exclusively in the heart.35 Likewise, when hypertension is induced by surgical stenosis of the renal artery, this induces cardiac hypertrophy and leads to dramatic reductions in both Cav-1 and Cav-3 protein expression.36 However, it remained unknown whether down-regulation of Cav-1 and Cav-3 expression was a cause or a consequence of cardiac hypertrophy. Here, we provide the first evidence that dual ablation of Cav-1 and Cav-3 gene expression produces left ventricular hypertrophy and dilation in Cav-1/3 dKO mouse hearts.
There are several possible mechanisms by which a complete loss of caveolae could result in cardiac hypertrophy. An important function of caveolae is to serve as a platform whereby preassembled signaling complexes are held in an inactive state through interactions with the resident caveolin proteins.1
G-protein 
subunits, H-Ras, and eNOS are concentrated in purified preparations of caveolae, harbor caveolin-binding motifs, and are in their inactive state when bound to caveolins.37-40
All three of these proteins (G-protein subunits, H-Ras, and eNOS) have been previously implicated in the development of cardiac hypertrophy.
A growing body of evidence has demonstrated that increased expression/activation of certain heterotrimeric GTP-binding proteins results in a cardiac hypertrophic response. For example, transgenic mice that overexpress either Gs, Gi, or Gq show cardiac hypertrophy, with varying levels of interstitial fibrosis, hyperproliferation, hypercellularity, and apoptosis.41-43
Similar studies have been performed by expressing an active mutant of Ras within the heart.44
These mice manifest cardiac hypertrophy and myofibrillar disarray. Therefore, the complete loss of caveolins in the heart may lead to constitutive activation of G-proteins or Ras signaling, leading to cardiac hypertrophy.
The expression profiles of Cav-1 and Cav-3 indicate that they function as negative regulators of proliferation by modulating signal transduction. For example, Cav-1 expression levels are down-regulated in NIH 3T3 cells that are rapidly dividing and up-regulated when the cells become confluent.45 Overexpression of Cav-1 inhibits the proliferation of human breast cancer cells.46 Antisense-mediated down-regulation of caveolin-1 is sufficient to cause the hyperactivation of the p42/44 MAP kinase pathway in NIH 3T3 cells. Blocking caveolin-1 transcript using an RNA interference technique in Caenorhabditis elegans results in a hyperactivated Ras signaling phenotype.47 Analogously, caveolin-3 is not expressed in proliferating myoblasts, but increases as myocyte differentiation ensues.48 That caveolins play an important role in the proliferative response is most evident in the fact that in caveolin-1 KO mouse lung there is a marked hyperproliferative phenotype. In addition, embryonic fibroblasts isolated from these mice demonstrate an increased proportion of cells found in S-phase of the cell cycle, and this hyper-proliferation phenotype is rescued by re-expression of caveolin-1.9 Thus, loss of caveolin may result in heightened activation of particular signaling pathways within the heart precipitating the formation of a hypertrophic response.
It is also possible that the cardiac hypertrophy observed in Cav-1/3 dKO mice may be the result an intrinsic defect within the cardiac myocyte itself, coupled with a secondary insult on the myocyte due to changes in the vasculature. Mutations within the Cav-3 gene (P104L; 
TFT 63–65; A45T) result in LGMD-1C.18,49
Given that there is a greater than 90% reduction in the expression of Cav-3 within the skeletal muscles of patients with LGMD-1C, the Cav-3 KO mouse has served as a model system for this disease process. Interestingly, the T-tubule system within both the Cav-3 KO mouse and human LGMD-1C skeletal muscles is structurally defective, thus suggesting possible functional derangements in this important membrane system.21,50
Cav-1 KO mice exhibit significant functional alterations in their vasculature. When challenged with vasoconstrictive agents, the Cav-1 KO vessels exhibit blunted constrictive responses.9,19 The Cav-1 KO vessels demonstrated markedly increased vasorelaxation responses compared to wild-type mice on exposure to acetylcholine.9 These phenomena can be explained by the heightened basal nitric oxide levels from the vascular endothelium, as well as decreased calcium mobilization within the smooth muscle cells. The loss of Cav-1 results in the dysinhibition of eNOS and calcium coupling within the cells of the vasculature.19 Therefore, a defective T-tubule system in cardiac myocytes (due to loss of Cav-3) coupled with vascular dysfunction (due to loss of Cav-1), may act together to elicit a cardiomyopathic phenotype in Cav-1/3 dKO mice.
Both endothelial cells and cardiac myocytes express eNOS. Caveolin-1 and caveolin-3 each serve to tonically inhibit eNOS activity within their respective cell types. Thus the combined loss of Cav-1 and Cav-3 may result in unregulated eNOS activity and nitric oxide production. Nitric oxide has been implicated in a variety of normal and pathological cardiac mechanisms.51 Endothelial derived nitric oxide increases diastolic relaxation, 52 while decreasing cardiac oxygen consumption.53 Myocardial derived nitric oxide has been shown to modulate pathways involved in autonomic regulation.54,55 Thus, alterations in nitric oxide regulation may be a contributing factor in the development of Cav-1/3 dKO cardiac pathology.
In summary, in this study we have generated Cav-1/Cav-3 double-knock-out mice. Unlike mice that are null mutants for only one of these caveolin genes, Cav-1/3 dKO mice fail to form caveolae in both muscle and non-muscle cells, and are deficient in the expression of all three caveolin protein products (Cav-1, -2, and -3). Interestingly, Cav-1/3 dKO mice develop a severe cardiomyopathy with left ventricular hypertrophy and chamber dilation, as assessed by gross morphology, cardiac MRI, and transthoracic echocardiography. Consistent with these findings, histological examination of Cav-1/3 dKO heart tissue reveals marked cardiac myocyte hypertrophy, disarray, and cytolysis; interstitial fibrosis; and chronic inflammation.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Supported by grants from the National Institutes of Health, the Muscular Dystrophy Association, and the American Heart Association, and a Hirschl/Weil-Caulier Career Scientist Award (all to M.P.L.). D.S.P. is supported by National Institutes of Health Graduate Training Program Grant TG-CA09475. S.E.W. and A.W.C. were supported by National Institutes of Health Medical Scientist Training Grant T32-GM07288. H.B.T. was supported by National Institutes of Health grant AI-12770.
D.S.P. and S.E.W. contributed equally to this work.
Accepted for publication March 28, 2002.
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin: caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem 1996, 271:29182-291901-adrenergic signal within caveolae: caveolin expression and the development of cardiac hypertrophy. Cardiovasc Res 2001, 51:709-716 overexpression. Circ Res 1996, 78:517-524 transgenic mice. Circ Res 1999, 84:34-42-protein levels in patients with hypertensive cardiac hypertrophy, ischemic heart disease, and cardiogenic shock. Cardiovasc Res 1995, 30:611-618[Medline]
This article has been cited by other articles:
 |
|
 |
|
  Y. Pu and X. Zhang Mouse Hepatitis Virus Type 2 Enters Cells through a Clathrin-Mediated Endocytic Pathway Independent of Eps15 J. Virol., August 15, 2008; 82(16): 8112 - 8123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Shi and J. Sottile Caveolin-1-dependent {beta}1 integrin endocytosis is a critical regulator of fibronectin turnover J. Cell Sci., July 15, 2008; 121(14): 2360 - 2371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Liu and P. F. Pilch A Critical Role of Cavin (Polymerase I and Transcript Release Factor) in Caveolae Formation and Organization J. Biol. Chem., February 15, 2008; 283(7): 4314 - 4322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zeidan, S. Javadov, S. Chakrabarti, and M. Karmazyn Leptin-induced cardiomyocyte hypertrophy involves selective caveolae and RhoA/ROCK-dependent p38 MAPK translocation to nuclei Cardiovasc Res, January 1, 2008; 77(1): 64 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Adebiyi, G. Zhao, S. Y. Cheranov, A. Ahmed, and J. H. Jaggar Caveolin-1 abolishment attenuates the myogenic response in murine cerebral arteries Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1584 - H1592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-K. Fang, K. R. Solomon, L. Zhuang, M. Qi, M. McKee, M. R. Freeman, and P. C. Yelick Caveolin-1{alpha} and -1{beta} Perform Nonredundant Roles in Early Vertebrate Development Am. J. Pathol., December 1, 2006; 169(6): 2209 - 2222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H. Patel, B. P. Head, H. N. Petersen, I. R. Niesman, D. Huang, G. J. Gross, P. A. Insel, and D. M. Roth Protection of adult rat cardiac myocytes from ischemic cell death: role of caveolar microdomains and {delta}-opioid receptors Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H344 - H350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Schwencke, R. C. Braun-Dullaeus, C. Wunderlich, and R. H. Strasser Caveolae and caveolin in transmembrane signaling: Implications for human disease Cardiovasc Res, April 1, 2006; 70(1): 42 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Feron and J.-L. Balligand Caveolins and the regulation of endothelial nitric oxide synthase in the heart Cardiovasc Res, March 1, 2006; 69(4): 788 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Penela, C. Murga, C. Ribas, A. S. Tutor, S. Peregrin, and F. Mayor Jr. Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease Cardiovasc Res, January 1, 2006; 69(1): 46 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Matthews, M. J. Taggart, and M. Westwood Effect of Cholesterol Depletion on Mitogenesis and Survival: The Role of Caveolar and Noncaveolar Domains in Insulin-Like Growth Factor-Mediated Cellular Function Endocrinology, December 1, 2005; 146(12): 5463 - 5473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sottile and J. Chandler Fibronectin Matrix Turnover Occurs through a Caveolin-1-dependent Process Mol. Biol. Cell, February 1, 2005; 16(2): 757 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 |
